Grace Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

GRCE$1.86-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Six months ended
	September 30, 2024	September 30, 2023
(Expressed in thousands)	$	$
Cash flows used in operating activities:
Net loss	(6,049)	(7,296)
Adjustments:
Depreciation expense	3	9
Gain on sale of equipment	—	(25)
Stock-based compensation	440	358
Change in fair value of derivative warrant liabilities	(1,756)	1,826
Deferred income tax benefit	(1,576)	(735)
Changes in operating assets and liabilities:
Receivables	307	(35)
Prepaid expenses	(194)	(446)
Trade and other payables	990	(1,986)
Operating lease right of use asset	—	(23)
Net cash used in operating activities	(7,835)	(8,353)
Cash flows from investing activities:
Proceeds from sale of equipment	—	110
Purchase of short-term investments	(15)	—
Net cash (used in) provided by investing activities	(15)	110
Cash flows from financing activities:
Net proceeds from issuance of common shares and warrants from private Placement	—	7,338
Proceeds from issuance of common shares from exercise of stock options	—	21
Net cash provided by financing activities	—	7,359
Net decrease in cash and cash equivalents	(7,850)	(884)
Cash and cash equivalents, beginning of period	23,005	27,875
Cash and cash equivalents, end of period	15,155	26,991
Cash and cash equivalents are comprised of:
Cash	1,018	10,596
Cash equivalents	14,137	16,395

(Formerly ACASTI PHARMA, INC.)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.